Esperion Therapeutics Inc. (ESPR) stock fell 6.19% in the after-market at an after-hours’ volume of 1.63 million, on November 23. During the previous trading session, the stock gained a huge 40.73% to close at $10.02 at a volume of 5.04 million. After which the stock fell down to $9.40 in the after-market. Intraday trading, ESPR stock varied between $7.02 and $10.02. While in the past 52 weeks, the stock fluctuated between a high of $39.50 and a low of $6.97 at an average volume of 1.09 million. The stock gained 17.74% in the past five days and a good 25.88% in the past month. But in the bigger picture, the stock has lost a value of 61.46% year to date. The current market capital of the stock stands at $207.03 million, with 29.08 million outstanding shares.
In November 23rd’s aftermarket, the stock saw a decline as a result of profit booking from the previous big gain.
Esperion Therapeutics Inc. (ESPR)
Founded in May 1998, Esperion Therapeutics Inc. (ESPR) is a pharmaceutical company. Which engages in the development and commercialization of oral therapies to treat patients with elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, MI.
ESPR’s Recent Updates
Recently, the company presented important new science highlighting the potential benefits of its Nexletol tablets. On November 12, ESPR reported that the analysis of their new data showed that the tablet alone lowered the cholesterol levels in nearly 1 out of 3 patients.
Nexletol is the first oral, non-statin Lower Density Lipoprotein Cholesterol (LDL-C) lowering medicine available to patients in almost 20 years. Under the name Nilemdo, Nexletol was approved by the FDA in February 2020.
Q3 Financials
On November 2, Esperion Therapeutics Inc. (ESPR) announced its financial results for the quarter ended September 30, 2021. As per Q3 2021, the U.S. net product revenue was $10.9 million, against $3.3 million for Q3 2020. While the total revenue was $14.4 million for Q3 2021, against $3.8 million for the same period of 2020. This increase was a result of the prescription growth of Nexletol and Nexlizet tablets.
Moreover, the Q3 2021, saw R&D expenses of $25.3 million, compared to $35.3 million in Q3 of 2020. While the general and administrative expenses for Q3 2021, were $39.3 million, compared to $48.8 million in Q3 of 2020.
Further, in the third quarter of 2021, net loss was $69.4 million, against $85.4 million in the same period of 2020. Accordingly, the net loss per share for the third quarter of 2021, was $2.62, against $3.07 in Q3 2020.
